Electroacupuncture Treatment of Peripheral Neuropathy After Taxane Chemotherapy for Breast Cancer

Inclusion Criteria: * Breast cancer patients diagnosed by pathology; * EOOG score is 0 or 1; * The age range for enrollment is between 18 and 75 years old; ④ Accept chemotherapy regimens based on taxane drugs (alone or in combination); ⑤ Previously received taxane chemotherapy for more than 6 months; ⑥ According to the National Cancer Institute (NCI) Common Terminology for Adverse Events (CTCAE) 5.0, reporting CIPN symptoms of grade 1 or higher for more than 2 weeks; ⑦ Voluntarily participate in this clinical trial and sign the informed consent form; * Accept regular follow-up visits; ⑨ There is complete pathological data available. Exclusion Criteria: * Non breast cancer patients; * Received electroacupuncture treatment within 6 months prior to the start of the study; * Patients who experience intolerable toxic side effects during standard dose chemotherapy and terminate the chemotherapy cycle; * Prior to enrollment, there was a history of peripheral neuropathy; * Unstable heart disease or myocardial infarction within the first 6 months of the study; ⑥ Active skin diseases or surface skin ulcers or infections that cannot tolerate electroacupuncture treatment; ⑦ Uncontrolled epilepsy patients with uncontrolled seizures; ⑧ Merge with other malignant tumor patients; ⑨ Pregnancy and lactation period; ⑩ Refusal to join clinical trial patients